The global clostridium botulinum market size is expected to grow at an impressive CAGR in the coming next 5 years timespan.
Botulism is a disease that causes paralysis and is caused by the bacteria Clostridium botulinum. Some symptoms include weakness, paralysis, vision and swallowing, breathing and speaking problems. The weakness further leads to fatigue of limb muscles. The symptoms are not caused by the bacterium itself but by the toxin produced by the bacterium.
MARKET DRIVERS:
The major factors that drive the growth of the botulism market include lack of cleanliness in certain regions of the world and increase in awareness about disease and treatments, increase in R&D practices, and availability of efficient solutions for botulism. Besides, owing to strong efforts by WHO and CDC, the disease is getting irradiated slowly.
Y-O-Y growth in the population, rising significance for minimally invasive or non-invasive surgeries, and increasing investments for R&D activities are driving the global clostridium botulinum market growth. Growing incidences of botulism and increasing awareness regarding the diverse toxic bacteria are expected to favor the clostridium botulinum market development. The increasing number of government measures supporting R&D in the clinical healthcare sector and improved advanced treatment facilities are favorable signals to the market growth.
The increasing number of epidemic diseases, growing healthcare expenditure, and the interest of key market participants to set up their research centers are a big plus to the market growth. For instance, in 2016, Ipsen S.A. received the U.S FDA approval for its Dysport injection, and this injection is to treat children aged 2 years and above for pediatric lower limb (PLL), same is used in adults. In 2017, around 7.2 million botulinum injections were used in the United States for cosmetic procedures. The growing number of cosmetic aesthetic procedures successfully intensifies the market growth during the forecast period.
MARKET RESTRAINTS:
However, the high cost of research and development projects and government austerity are some of the hurdles expected to hinder the growth of the botulism market.
Impact of COVID-19 on the global clostridium botulinum market:
The World Health Organization (WHO) declared the coronavirus (COVID-19) as an emergency public health issue. Governments imposed nationwide lockdown was following strict rules to prevent the virus from the spread. All the hospitals were ordered to stop or cancel or postpone all the non-emergency medical procedures to bring the medical capacities in COVID-19 patients. The pandemic crisis has negatively affected the clostridium botulinum market. People who are suffering from this disease need to take injections every 3 to 4months. During the lockdown, a vast number of missed or canceled their treatment due to the coronavirus's fear. The advantages of botulinum toxin therapeutic are reused to improve COVID-19 intervened diverse pathological effects comprising pulmonary failure, cardiovascular defects, and neurological shortage observed in COVID-19 patients.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2020 to 2026 |
|
Base Year |
2020 |
|
Forecast Period |
2021 to 2026 |
|
Segments Covered |
By Product Type, Application, End-User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
This research report on the global clostridium botulinum market has been segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2025.
Clostridium Botulinum Market – By Product Type:
The botulinum toxin type A segment is expected to lead the global clostridium botulinum market. As per CDC, in 2016, in the United States, 102 botulinum cases were caused by toxin Type A.
Clostridium Botulinum Market – By Application:
Based on the application, the aesthetic segment accounted for a major share of the market. The aesthetic applications are used in the cosmetic industry for bettering facial appearance and decreasing aging symptoms. Growing R&D actions are broadening the usage of botulinum toxin (BOTOX) among different indications. As per the International Society of Plastic Surgery 2018, estimated growth in BOTOX procedures rose by 17.4% in 2018 compared to 2017. The people's issues about their look are flourishing in both the developed and developing countries of the world.
Clostridium Botulinum Market – By Distribution Channel:
Based on the distribution channel, the hospital segment is forecasted to account for the global market share during the forecast period. The availability of advanced healthcare infrastructure, highly qualified and trained medical professionals, and rising demand for aesthetic Botox procedures strengthen the clostridium botulinum market development.
Clostridium Botulinum Market – By Region:
Geographically, the global clostridium botulinum market was dominated by North America, followed by Europe. The Asia Pacific is considered to be a lucrative market is expected to grow at a high CAGR.
KEY MARKET PARTICIPANTS:
The top companies dominating the Global Clostridium Botulinum Market profiled in this report are XOMA Ltd., AlphaVax, Inc., Cangene Corporation, Morphotek, Inc., DynPort Vaccine Company LLC, Emergent BioSolutions, Inc., Molecular Targeting Technologies, Inc., and many others.
RECENT MARKET DEVELOPMENTS:
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Botulinum toxin type A
5.1.3 Botulinum toxin type B
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Application
5.2.1 Introduction
5.2.2 Aesthetic
5.2.3 Therapeutics
5.2.4 Y-o-Y Growth Analysis, By application
5.2.5 Market Attractiveness Analysis, By application
5.2.6 Market Share Analysis, By application
5.3 Distribution channel
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Clinics
5.3.4 Retail pharmacies
5.3.5 Y-o-Y Growth Analysis, By distribution channel
5.3.6 Market Attractiveness Analysis, By distribution channel
5.3.7 Market Share Analysis, By distribution channel
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By application
6.1.3.4 By distribution channel
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By application
6.1.4.4 By distribution channel
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By application
6.1.5.4 By distribution channel
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 DynPort Vaccine Company
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Emergent BioSolutions, Inc.
8.3 XOMA Ltd.
8.4 AlphaVax
8.5 Cangene Corporation
8.6 Morphotek, Inc.
8.7 Morphotek, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
